QUOTED. March 27, 2018. David Chernoff.
SetPoint Medical Corp. will begin enrolling 15 rheumatoid arthritis (RA) patients in a study to assess the safety and effectiveness of its unique vagus nerve stimulation system. Check out what David Chernoff, the company's chief medical officer, said about it here.
"We are recruiting patients to evaluate SetPoint's proprietary miniaturized, rechargeable wireless bioelectronic device for RA, building on our body of previous work defining the mechanism of action and proof of concept. This is important because, despite the availability of oral disease-modifying drugs such as methotrexate and multiple targeted biologic agents, only one-third of RA patients on current therapies meet criteria for clinical remission." –David Chernoff, chief medical officer, SetPoint Medical Corp.
- Find out more: SetPoint Medical Starts Testing Unique Neuromodulation Device In Rheumatoid Arthritis Patients
Click here for a free trial of Medtech Insight